奥美沙坦与缬沙坦对扩张型心肌病患者心肌代谢影响的比较研究(OVOID)试验:随机对照试验研究方案的设计与原理
OVOID 是一项非盲、开放标签、平行组、前瞻性、随机、对照、多中心临床试验,计划纳入 40 例 20 至 85 岁扩张型心肌病患者,随机分入奥美沙坦组或缬沙坦组。基线及接受研究药物 6 个月时行 18F-FDG 心脏 PET,主要终点为 6 个月时每平方米心肌葡萄糖消耗量。该试验旨在比较两药改善心肌代谢的疗效,将是首个探讨 ARB 对心力衰竭差异效应的随机对照研究。
要点
- OVOID 试验计划纳入 40 例 20 至 85 岁扩张型心肌病患者,随机分为奥美沙坦组与缬沙坦组。
- 主要终点为接受研究药物 6 个月时经 18F-FDG PET 测得的每平方米心肌葡萄糖消耗量。
- 这是首个研究 ARB 对心力衰竭差异效应的随机对照比较研究。
核心结论
- 该试验旨在比较奥美沙坦与缬沙坦改善扩张型心肌病患者心肌代谢的疗效,将是首个探讨 ARB 对心力衰竭差异效应的随机对照研究。
研究设计与样本
- OVOID 研究设计为非盲、开放标签、平行组、前瞻性、随机、对照、多中心临床试验。
- 计划纳入 40 例 20 至 85 岁扩张型心肌病患者,随机分配至奥美沙坦组或缬沙坦组。
- 基线及接受研究药物 6 个月时行 18F-FDG 心脏 PET 检查。
关键数值与推荐
- 主要终点为接受研究药物 6 个月时经 18F-FDG PET 测得的每平方米心肌葡萄糖消耗量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dilated cardiomyopathy (DCMP) is characterized by ventricular chamber enlargement and systolic dysfunction which may cause heart failure. Patients with DCMP have overactivation of the renin-angiotensin-aldosterone systems, which can also adversely affect myocardial metabolism in heart failure. The impairment of myocardial metabolism can contribute to the progression of left ventricular remodeling and contractile dysfunction in heart failure. Although angiotensin II receptor blockers (ARBs) have been used to treat patients with DCMP, there has been no direct comparison of the efficacy of these agents. The objective of this study is to compare the effects of olmesartan and valsartan on myocardial metabolism in patients with DCMP. METHODS/DESIGN: The OVOID study (a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy) is designed as a non-blinded, open-label, parallel-group, prospective, randomized, controlled, multicenter clinical trial. A total of 40 DCMP patients aged between 20 and 85 years will be randomly allocated into the olmesartan or the valsartan group. 18F-fluoro-2-deoxyglucose (FDG) cardiac positron emission tomography (PET) will be performed at baseline and six months after receiving the study agent. The primary endpoint is myocardial glucose consumption per square meter, measured using 18F-FDG PET 6 months after receiving the study agent. DISCUSSION: The purpose of this trial is to compare the efficacy between olmesartan and valsartan in improving myocardial metabolism in DCMP patients. This will be the first randomized comparative study investigating the differential effects of ARBs on heart failure. TRIAL REGISTRATION: ClinicalTrials.gov NCT04174456 . Registered on 18 November 2019.
引用
- Jo S, Moon H, Park K, et al. Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial. Trials. 2022. PMID: 35033178. doi:10.1186/s13063-021-05970-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。